ReportsnReports: Global Markets Overview of Blood Cancer Therapeutics

This report provides information on the therapeutic development for Blood Cancer, complete with latest updates, and special features on late-stage and discontinued projects.

Dallas, TX (prHWY.com) January 17, 2013 - Global Markets Direct's, ''Blood Cancer - Pipeline Review, H2 2012'', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Blood Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Blood Cancer. Blood Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Request a sample of this report @ http://www.reportsnreports.com/contacts/RequestSample.aspx?name=211622.

Scope

- A snapshot of the global therapeutic scenario for Blood Cancer.
- A review of the Blood Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Blood Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Blood Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Blood Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Buy a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=211622.

Contact sales@reportsandreports.com for further information.

###

Tag Words: cancer

Categories: Research

Press Release Contact
Contact:
Mr.Priyank
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com

Link To This Press Release:

URL HTML Code